MedTrace Logo

Impact of Hepatectomy on HCC Recurrence

NCT06390228 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 197

Last updated 2024-04-30

No results posted yet for this study

Summary

Hepatectomy is the first option for the treatment of hepatocellular carcinoma(HCC) at CNLC Ib stage. HCC patients who undergo curative hepatectomy may experience varying remnant liver volumes and thus leads to different oncological outcomes.

Conditions

  • Hepatocellular Carcinoma Stage I
  • Recurrence

Interventions

PROCEDURE

Major hepatectomy

the extent of liver resection

Sponsors & Collaborators

  • National Natural Science Foundation of China

    collaborator OTHER_GOV

  • Anhui Medical University

    lead OTHER

Principal Investigators

  • Dalong Yin, Ph.D · The First Affiliated Hospital of University of Science and Technology of China

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-01
Primary Completion
2023-08-01
Completion
2023-08-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06390228 on ClinicalTrials.gov